Scarica l'app Stockscreener
2.23
0.45%
-0.01
Precedente Chiudi:
$2.24
Aprire:
$2.27
Volume 24 ore:
127.07K
Relative Volume:
0.28
Capitalizzazione di mercato:
$140.19M
Reddito:
-
Utile/perdita netta:
$-131.52M
Rapporto P/E:
-1.2528
EPS:
-1.78
Flusso di cassa netto:
$-107.56M
1 W Prestazione:
+2.76%
1M Prestazione:
-0.45%
6M Prestazione:
+145.87%
1 anno Prestazione:
+134.74%
Intervallo 1D:
$2.1809
$2.37
Intervallo di 1 settimana:
$1.95
$2.37
Portata 52W:
$0.6101
$4.22
Prelude Therapeutics Inc Stock (PRLD) Company Profile
Nome
Prelude Therapeutics Inc
Settore
Industria
Telefono
(302) 467-1280
Indirizzo
175 INNOVATION BOULEVARD, WILMINGTON
Compare PRLD vs VRTX, REGN, ARGX, ALNY, ONC
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
PRLD
Prelude Therapeutics Inc
|
2.23 | 140.82M | 0 | -131.52M | -107.56M | -1.78 |
|
VRTX
Vertex Pharmaceuticals Inc
|
491.47 | 117.98B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
803.17 | 82.85B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
821.96 | 51.58B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
314.40 | 40.75B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
346.07 | 38.33B | 4.98B | 69.60M | 525.67M | 0.5198 |
Prelude Therapeutics Inc Stock (PRLD) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2024-09-19 | Aggiornamento | H.C. Wainwright | Neutral → Buy |
| 2024-06-20 | Downgrade | Barclays | Equal Weight → Underweight |
| 2024-03-13 | Iniziato | JMP Securities | Mkt Outperform |
| 2024-02-20 | Downgrade | H.C. Wainwright | Buy → Neutral |
| 2023-12-19 | Downgrade | Morgan Stanley | Equal-Weight → Underweight |
| 2022-11-21 | Downgrade | BofA Securities | Neutral → Underperform |
| 2022-09-09 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2022-07-29 | Iniziato | Jefferies | Buy |
| 2022-03-15 | Downgrade | BofA Securities | Buy → Neutral |
| 2022-02-28 | Downgrade | Barclays | Overweight → Equal Weight |
| 2021-10-08 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
| 2021-07-27 | Aggiornamento | BofA Securities | Neutral → Buy |
| 2021-04-26 | Iniziato | H.C. Wainwright | Buy |
| 2021-03-09 | Iniziato | Barclays | Overweight |
| 2020-11-20 | Downgrade | BofA Securities | Buy → Neutral |
| 2020-10-20 | Iniziato | BofA Securities | Buy |
| 2020-10-20 | Iniziato | Goldman | Neutral |
| 2020-10-20 | Iniziato | Morgan Stanley | Equal-Weight |
Mostra tutto
Prelude Therapeutics Inc Borsa (PRLD) Ultime notizie
How Prelude Therapeutics’ deal with Incyte changed its course - Delaware Business Times
What’s the beta of Prelude Therapeutics Incorporated stock2025 AllTime Highs & AI Powered Market Entry Strategies - mfd.ru
Aug Chart Watch: Is NeuroSense Therapeutics Ltd Equity Warrant benefiting from interest rate changesGlobal Markets & Real-Time Stock Price Movement Reports - baoquankhu1.vn
Is Prelude Therapeutics Incorporated in a long term uptrendJuly 2025 Market Mood & Technical Buy Zone Confirmation - mfd.ru
Prelude Therapeutics (NASDAQ:PRLD) Trading Down 0.9%Should You Sell? - MarketBeat
Is Prelude Therapeutics Incorporated stock trending bullishWeekly Profit Recap & High Accuracy Buy Signal Tips - baoquankhu1.vn
Prelude Therapeutics Secures FDA Clearance for Key Drug Candidate - AD HOC NEWS
Weekly Buzz: ATYR To Meet With FDA, SGMO Aces Fabry Study, AQST's Anaphylm Gets Rejected - RTTNews
Take Profit: Does Prelude Therapeutics Incorporated have a sustainable dividendTrade Analysis Summary & Daily Entry Point Trade Alerts - baoquankhu1.vn
Why Did PRLD Stock Surge 13% Today? - Stocktwits
Aug Wrap: Is ETRACS 2xMonthly Pay Leveraged Index ETN benefiting from interest rate changes2025 Market WrapUp & Weekly Stock Breakout Alerts - baoquankhu1.vn
The $71 Billion Cancer Shift: Why The FDA Is Speeding Up - The Spec
Why did PRLD stock surge 13% today? - MSN
Prelude’s JAK2 V617F inhibitor PRT-12396 gains IND clearance - BioWorld MedTech
Prelude Therapeutics stock gets reiterated Market Outperform rating at Citizens - Investing.com Canada
FDA clears Prelude Therapeutics’ IND for JAK2 inhibitor in blood disorders - Investing.com Canada
Prelude Therapeutics (PRLD) Advances Blood Cancer Drug Trial wit - GuruFocus
Prelude Therapeutics Incorporated Receives FDA Clearance of Investigational New Drug Application for PRT12396 - marketscreener.com
Prelude Therapeutics stock surges after FDA clears IND for cancer drug By Investing.com - Investing.com South Africa
Prelude climbs as FDA clears study for Incyte-partnered cancer candidate - Seeking Alpha
Prelude Therapeutics stock surges after FDA clears IND for cancer drug - Investing.com India
Prelude Therapeutics receives FDA clearance of investigational new drug application (IND) for PRT12396, a mutant-selective JAK2V617F inhibitor - marketscreener.com
Prelude Therapeutics (PRLD) Gains FDA Approval for Phase 1 Study of PRT12396 - GuruFocus
Prelude Therapeutics Wins FDA IND Clearance for PRT12396 - TipRanks
Prelude Therapeutics Inc FDA Clearance for PRT12396 Phase 1 Study - TradingView
Prelude Therapeutics Receives FDA Clearance of Investigational New Drug Application (IND) for PRT12396, a Mutant-selective JAK2V617F Inhibitor - ChartMill
Prelude Therapeutics’ PRT2527 Trial Completion: What Investors Should Watch in Hematologic Oncology - TipRanks
Hedge Fund Bets: Will Prelude Therapeutics Incorporated announce a stock splitJuly 2025 Macro Moves & Precise Swing Trade Alerts - baoquankhu1.vn
Retail investors in Prelude Therapeutics Incorporated (NASDAQ:PRLD) are its biggest bettors, and their bets paid off as stock gained 12% last week - Yahoo Finance
Aug Highlights: Does MAMO outperform in volatile markets2025 Support & Resistance & Free Weekly Watchlist of Top Performers - baoquankhu1.vn
Prelude Therapeutics (NASDAQ:PRLD) Rating Lowered to Hold at Wall Street Zen - MarketBeat
Aug Reactions: Can Prelude Therapeutics Incorporated outperform under higher oil pricesQuarterly Portfolio Summary & High Accuracy Swing Trade Signals - baoquankhu1.vn
Market Review: Is Prelude Therapeutics Incorporated a cyclical or defensive stockMarket Volume Report & Community Verified Trade Signals - baoquankhu1.vn
How Prelude Therapeutics Incorporated stock compares to industry benchmarksPortfolio Risk Report & Free Community Consensus Stock Picks - ulpravda.ru
How Prelude Therapeutics Incorporated stock responds to policy changesMarket Activity Recap & Fast Entry High Yield Stock Tips - ulpravda.ru
Prelude Therapeutics (NASDAQ:PRLD) Stock Rating Upgraded by Wall Street Zen - MarketBeat
Prelude Therapeutics Inc Announces New Clinical Developments - TradingView — Track All Markets
Aug Sentiment: How Prelude Therapeutics Incorporated stock responds to policy changesWeekly Investment Summary & Real-Time Market Sentiment Alerts - Улправда
Will Prelude Therapeutics Incorporated stock reach all time highs in 2025Portfolio Update Report & Expert Verified Movement Alerts - Улправда
Will Prelude Therapeutics Incorporated stock benefit from AI adoptionJuly 2025 Rallies & Free Real-Time Market Sentiment Alerts - Улправда
Quarterly Trades: Is Prelude Therapeutics Incorporated stock positioned well for digital economyStop Loss & Free Daily Entry Point Trade Alerts - ulpravda.ru
Prelude Therapeutics Reshapes Pipeline With Incyte Deal and Strategic Refocus - MSN
Prelude Therapeutics Incorporated (NASDAQ:PRLD) Short Interest Up 28.5% in December - MarketBeat
Bullish Prelude Therapeutics Insiders Rewarded As Their Investment Rises To US$2.75m - Sahm
Prelude Therapeutics Incorporated's (NASDAQ:PRLD) Path To Profitability - Yahoo Finance
Prelude Therapeutics (NASDAQ:PRLD) Stock Price Up 2.1%What's Next? - MarketBeat
Is Prelude Therapeutics Stock Built to Withstand a Pullback? - Trefis
What dividend safety score for Prelude Therapeutics Incorporated stock2025 Key Lessons & Risk Controlled Swing Alerts - Улправда
Risk Analysis: What technical signals suggest for Prelude Therapeutics Incorporated stockForecast Cut & High Yield Stock Recommendations - Улправда
Prelude Therapeutics Inc Azioni (PRLD) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
1.12%
0.87%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):